Tildrakizumab for Psoriasis in Patients With Current or Prior Malignancy: Methodological Considerations and Clinical Implications

Key Points

• Tildrakizumab shows promise for treating psoriasis in patients with current or prior malignancy, indicating a potential therapeutic option.
• This analysis considers methodological aspects relevant to using tildrakizumab in a sensitive population of patients with malignancy.
• Clinical implications suggest a need for tailored treatment approaches for psoriasis patients with complicating cancer histories.
• Careful consideration of methodologies and patient safety remains vital when applying tildrakizumab in these contexts.

Abstract